NAMS
NewAmsterdam Pharma Company N.V. Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.91B
P/E Ratio
—
EPS
$-1.72
Beta
0.13
52W High
$42.00
52W Low
$14.62
50-Day MA
$32.35
200-Day MA
$30.48
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V. is a groundbreaking biotechnology firm specializing in the development of innovative therapies for cardiometabolic diseases. Utilizing its proprietary technology platform, the company addresses critical unmet medical needs with a focus on advanced drug discovery and a robust clinical development pipeline. Led by a team of experienced industry professionals, NewAmsterdam is strategically positioned to become a key player in the biopharmaceutical landscape, presenting investors with a compelling growth opportunity through its novel therapeutic initiatives aimed at transforming treatment paradigms and enhancing patient outcomes.
Fundamentals
| Revenue (TTM) | $22.50M |
| Gross Profit (TTM) | $22.50M |
| EBITDA | $-225.46M |
| Operating Margin | -206188.00% |
| Return on Equity | -28.30% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $5.97 |
| Price-to-Book | 5.55 |
| Price-to-Sales (TTM) | 173.77 |
| EV/Revenue | 140.34 |
| EV/EBITDA | 27.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.80% |
| Shares Outstanding | $114.97M |
| Float | $71.47M |
| % Insiders | 0.97% |
| % Institutions | 106.27% |
Historical Volatility
HV 10-Day
55.93%
HV 20-Day
58.11%
HV 30-Day
61.09%
HV 60-Day
52.47%
HV Rank
69.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($49.38 target)
2
Strong Buy11
Buy1
HoldData last updated: 4/9/2026